Cargando…

The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial

BACKGROUND: Hyperthyroidism is related to vascular atherosclerosis. Propylthiouracil (PTU) and methimazole, other than their antithyroid effects, may have different mechanisms in preventing atherogenesis in Graves’ disease. OBJECTIVE: This study aimed to investigate the effect of antithyroid drugs o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wisnu, Wismandari, Alwi, Idrus, Nafrialdi, Nafrialdi, Harimurti, Kuntjoro, Pemayun, Tjokorda Gede D., Jusman, Sri Widia A., Santoso, Dewi Irawati S., Harahap, Alida R., Suwarto, Suhendro, Subekti, Imam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721229/
https://www.ncbi.nlm.nih.gov/pubmed/34987480
http://dx.doi.org/10.3389/fendo.2021.796194
_version_ 1784625295546908672
author Wisnu, Wismandari
Alwi, Idrus
Nafrialdi, Nafrialdi
Harimurti, Kuntjoro
Pemayun, Tjokorda Gede D.
Jusman, Sri Widia A.
Santoso, Dewi Irawati S.
Harahap, Alida R.
Suwarto, Suhendro
Subekti, Imam
author_facet Wisnu, Wismandari
Alwi, Idrus
Nafrialdi, Nafrialdi
Harimurti, Kuntjoro
Pemayun, Tjokorda Gede D.
Jusman, Sri Widia A.
Santoso, Dewi Irawati S.
Harahap, Alida R.
Suwarto, Suhendro
Subekti, Imam
author_sort Wisnu, Wismandari
collection PubMed
description BACKGROUND: Hyperthyroidism is related to vascular atherosclerosis. Propylthiouracil (PTU) and methimazole, other than their antithyroid effects, may have different mechanisms in preventing atherogenesis in Graves’ disease. OBJECTIVE: This study aimed to investigate the effect of antithyroid drugs on markers of vascular atherosclerosis in Graves’ hyperthyroidism. METHODS: This study was a single-blind, randomized clinical trial conducted on 36 patients with Graves’ disease in Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, from June 2019 until July 2020. Graves’ disease was diagnosed from clinical manifestation of hyperthyroidism with diffuse goiter and then confirmed by thyroid stimulation hormone (TSH), free T4 (fT4), and TSH-receptor antibody (TRAb) measurements. Participants were randomly assigned to either a PTU or a methimazole treatment group and followed up for 3 months. Markers of vascular atherosclerosis were represented by adhesion molecules [intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin], carotid artery stiffness [pulse wave velocity (PWV)], and thickness [carotid intima media thickness (cIMT)]. RESULTS: By the end of the study, 24 participants reached euthyroid condition (13 from the PTU group and 11 from the methimazole group). After 3 months of follow-up, in the PTU group, we noticed an improvement of ICAM-1 [pretreatment: 204.1 (61.3) vs. posttreatment: 141.6 (58.4) ng/ml; p = 0.001], VCAM-1 [837 (707–977) vs. 510 (402–630) ng/ml; p < 0.001] and E-selectin [32.1 (24.1–42.7) vs. 28.2 (21.6–36.8) ng/ml; p = 0.045] in the PTU group. In the methimazole group, only VCAM-1 improvement [725 (565–904) vs. 472 (367–590); p = 0.001] was observed. Meanwhile, we found no significant changes in PWV or cIMT in either group. CONCLUSION: Antithyroid treatment in Graves’ disease leads to improvement in adhesion molecules, with a lesser effect on methimazole, whereas there were no significant changes in PWV or cIMT. PTU may have a better mechanism compared with methimazole in terms of improving adhesion molecules.
format Online
Article
Text
id pubmed-8721229
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87212292022-01-04 The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial Wisnu, Wismandari Alwi, Idrus Nafrialdi, Nafrialdi Harimurti, Kuntjoro Pemayun, Tjokorda Gede D. Jusman, Sri Widia A. Santoso, Dewi Irawati S. Harahap, Alida R. Suwarto, Suhendro Subekti, Imam Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Hyperthyroidism is related to vascular atherosclerosis. Propylthiouracil (PTU) and methimazole, other than their antithyroid effects, may have different mechanisms in preventing atherogenesis in Graves’ disease. OBJECTIVE: This study aimed to investigate the effect of antithyroid drugs on markers of vascular atherosclerosis in Graves’ hyperthyroidism. METHODS: This study was a single-blind, randomized clinical trial conducted on 36 patients with Graves’ disease in Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, from June 2019 until July 2020. Graves’ disease was diagnosed from clinical manifestation of hyperthyroidism with diffuse goiter and then confirmed by thyroid stimulation hormone (TSH), free T4 (fT4), and TSH-receptor antibody (TRAb) measurements. Participants were randomly assigned to either a PTU or a methimazole treatment group and followed up for 3 months. Markers of vascular atherosclerosis were represented by adhesion molecules [intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin], carotid artery stiffness [pulse wave velocity (PWV)], and thickness [carotid intima media thickness (cIMT)]. RESULTS: By the end of the study, 24 participants reached euthyroid condition (13 from the PTU group and 11 from the methimazole group). After 3 months of follow-up, in the PTU group, we noticed an improvement of ICAM-1 [pretreatment: 204.1 (61.3) vs. posttreatment: 141.6 (58.4) ng/ml; p = 0.001], VCAM-1 [837 (707–977) vs. 510 (402–630) ng/ml; p < 0.001] and E-selectin [32.1 (24.1–42.7) vs. 28.2 (21.6–36.8) ng/ml; p = 0.045] in the PTU group. In the methimazole group, only VCAM-1 improvement [725 (565–904) vs. 472 (367–590); p = 0.001] was observed. Meanwhile, we found no significant changes in PWV or cIMT in either group. CONCLUSION: Antithyroid treatment in Graves’ disease leads to improvement in adhesion molecules, with a lesser effect on methimazole, whereas there were no significant changes in PWV or cIMT. PTU may have a better mechanism compared with methimazole in terms of improving adhesion molecules. Frontiers Media S.A. 2021-12-20 /pmc/articles/PMC8721229/ /pubmed/34987480 http://dx.doi.org/10.3389/fendo.2021.796194 Text en Copyright © 2021 Wisnu, Alwi, Nafrialdi, Harimurti, Pemayun, Jusman, Santoso, Harahap, Suwarto and Subekti https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Wisnu, Wismandari
Alwi, Idrus
Nafrialdi, Nafrialdi
Harimurti, Kuntjoro
Pemayun, Tjokorda Gede D.
Jusman, Sri Widia A.
Santoso, Dewi Irawati S.
Harahap, Alida R.
Suwarto, Suhendro
Subekti, Imam
The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial
title The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial
title_full The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial
title_fullStr The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial
title_full_unstemmed The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial
title_short The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial
title_sort differential effects of propylthiouracil and methimazole as graves’ disease treatment on vascular atherosclerosis markers: a randomized clinical trial
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721229/
https://www.ncbi.nlm.nih.gov/pubmed/34987480
http://dx.doi.org/10.3389/fendo.2021.796194
work_keys_str_mv AT wisnuwismandari thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT alwiidrus thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT nafrialdinafrialdi thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT harimurtikuntjoro thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT pemayuntjokordageded thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT jusmansriwidiaa thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT santosodewiirawatis thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT harahapalidar thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT suwartosuhendro thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT subektiimam thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT wisnuwismandari differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT alwiidrus differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT nafrialdinafrialdi differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT harimurtikuntjoro differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT pemayuntjokordageded differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT jusmansriwidiaa differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT santosodewiirawatis differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT harahapalidar differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT suwartosuhendro differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial
AT subektiimam differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial